GMAB

MKT CAP:$16B

Genmab AS

Market Cap

$16B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$24.80-$7.02 (-22.06%)

Jun 8, 2026

52W High $35.3452W Low $20.30

Company Details

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory ...

CEO

—

IPO Date

Jun 1, 2009

Website

www.genmab.com

Key Metrics TTM (DKK)

Revenue

DKK 8.8B

-34.4% YoY

Net Income

DKK 2.6B

EPS (Diluted)

Free Cash Flow

DKK 1.1B

Revenue / Share

DKK 13.84

Gross Margin

93.6%

Operating Margin

36.3%

Net Margin

29.6%

FCF Margin

13.0%

P/S

P/E

Earnings Reports

Q2 2026

Aug 6, 2026

PENDING

Q1 2026

May 7, 2026

DKK 899M+25.8%

FY 2025

Feb 17, 2026

DKK 3.7B-82.7%

Q4 2025

Feb 17, 2026

DKK 1.1B-83.6%

Q3 2025

Nov 6, 2025

DKK 1.0B-81.6%

Revenue & Profitability (DKK)

Operating Cash Flow (DKK)

CapEx Spend (DKK)

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation (DKK)

OpEx Breakdown (DKK)

War Chest (DKK)

Shares Outstanding

Revenue Per Employee (DKK)

Revenue / Employee